CL-218,872 EU

6 - 52

Discover CL-218,872 – The Next Generation Sedative

Introduktion CL-218,872, a groundbreaking sedative-hypnotic offering unparalleled efficacy in inducing sleep and reducing anxiety. Unlike traditional benzodiazepines, CL-218,872 targets specific GABA A receptors, ensuring a focused approach with fewer side effects. Ideal for research and therapeutic applications, it’s a beacon of hope for those seeking reliable and safe sedation.

Denna produkt är också tillgänglig i Kapsel och Droppar för en enklare undersökning.

Alla produkter från EU Retail kan endast skickas till EU-länder.

Alla designerdroger som säljs på denna webbplats är avsedda för forskning och kriminaltekniska tillämpningar.

 

Product Overview:

CL-218,872 is a novel sedative and hypnotic compound. Unlike traditional benzodiazepines, it belongs to a unique class of nonbenzodiazepine hypnotics. The compound is particularly noted for its selective action on the GABA A receptor, specifically targeting the α1 subtype.

Chemical and Pharmacological Properties:

The molecular structure of CL-218,872 differentiates it from benzodiazepines, contributing to its unique pharmacological profile. Its action as a partial agonist at the GABA A receptor sites leads to sedative, anxiolytic, anticonvulsant, and amnestic effects, with a reduced risk of dependency compared to traditional benzodiazepines.

Dosering och administrering:

The optimal dosage of CL-218,872 varies depending on the intended use and the subject’s physiology. In research settings, dosages are carefully controlled and monitored.

Therapeutic Effects:

CL-218,872 is primarily used in research for its sedative and hypnotic effects. It has shown potential in studies for inducing sleep and reducing anxiety, with a faster onset and shorter duration of action, making it advantageous for specific therapeutic applications.

Side Effects and Harm Reduction:

Like all sedative-hypnotics, CL-218,872 can cause side effects such as dizziness, confusion, and motor impairment. Long-term use or misuse can lead to tolerance and dependence. Its safety profile, however, indicates a lower risk of these adverse effects compared to traditional benzodiazepines. Harm reduction strategies involve controlled administration, monitoring for adverse reactions, and avoiding use with other central nervous system depressants.

Comparative Analysis:

In comparison to other hypnotics like triazolam or zolpidem, CL-218,872 offers a unique balance of efficacy and safety, making it a subject of interest in both pharmacological research and potential clinical use.

Varför köpa CL-218,872 EU from RECHEMCO?

★ Vi har en lång handelshistoria på marknaden så du drar nytta av vår erfarenhet.
★ CL-218,872 har testats och kontrollerats.
★ We accept various payment methods such as Bitcoin, Monero, many other cryptocurrencies and bank wire.

Vad du får när du köper CL-218,872 EU from RECHEMCO?

- En förseglad aluminiumfoliepåse innehållande högsta kvalitet CL-218,872 EU
• White powder
• 98-99% Purity

Antal

50 mg, 100 mg, 250 mg, 500 mg, 1 g

Recensioner

Det finns inga recensioner än.

Bli först med att recensera ”CL-218,872 EU”

Din e-postadress kommer inte publiceras. Obligatoriska fält är märkta *

SPINNA FÖR ATT VINNA!

  • Prova lyckan och vinn en rabattkupongkod
  • 1 gratissnurr var 15:e dag
  • Inget fusk! Använd endast din riktiga e-postadress.
  • KOM IHÅG: Kupongkoden är giltig i 7 dagar.
Prova lyckan!
Aldrig
Påminn senare
Inga tack